Monocytes as Targets for Immunomodulation by Regional Citrate Anticoagulation

Area of Science:

• Nephrology
• Immunology
• Hematology

Background:

• End-stage renal disease patients on hemodialysis exhibit complex immune alterations, increasing infection susceptibility.
• Anticoagulation, uremic toxins, and dialysis procedures contribute to immune dysregulation.
• Regional citrate anticoagulation (RCA) is associated with higher infection rates compared to systemic heparin anticoagulation (SHA).

Purpose of the Study:

• To investigate the hypothesis that RCA impacts the immune status of hemodialysis patients by targeting monocytes.
• To compare the effects of RCA and SHA on monocyte immune function in end-stage renal disease patients.

Main Methods:

• A cohort study involving 38 end-stage renal patients undergoing hemodialysis.
• Analysis of monocyte surface activation markers (e.g., HLA-DR) post-dialysis.
• RNA sequencing (RNA-seq) and gene set enrichment analysis of pre-dialysis monocytes.

Main Results:

• Monocytes from RCA patients failed to upregulate surface activation markers post-dialysis, indicating deactivation.
• RNA-seq revealed significant transcriptional changes in pre-dialysis monocytes from RCA patients, affecting cell cycle, metabolism, and cytokine signaling.
• These transcriptomic changes suggest a lasting reprogramming of monocyte immune response due to RCA, persisting beyond dialysis.

Conclusions:

• RCA, unlike SHA, impairs monocyte response to activation stimuli in hemodialysis patients.
• RCA alters the immune status of these patients, potentially explaining increased infection rates.
• Monocyte deactivation and transcriptomic reprogramming by RCA have potential clinical implications for infection risk management.